BioSpace News Archive

Drug Development

FDA Wants More Answers Before Releasing Clinical Hold on MaaT’s GvHD Drug MaaT013

MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.

August 11, 2022
·
2 min read
·
Tristan Manalac
Drug Development

Panecell Believes Stem Cell Therapy could be Effective Against Long COVID

Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.

August 11, 2022
·
3 min read
·
Mark Terry
How Human Milk can Treat the Microbiome and Improve Outcomes without Antibiotics

In a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.

August 11, 2022
·
4 min read
·
Abbey Glasure
Business

BioSpace Movers & Shakers: Scribe, eFFECTOR, Chimerix, MediWound & More

This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.

August 11, 2022
·
6 min read
·
Alex Keown
Drug Development

Vyne Left Reassessing Priorities after Atopic Dermatitis Combo Fails in Phase II

Vyne Therapeutics’ combination therapy for atopic dermatitis failed to meet the primary endpoint in a Phase II trial, leaving the company evaluating its priorities and pipeline.

August 11, 2022
·
2 min read
·
Vanessa Doctor, RN
Bolt Hones in on ISAC programs as Toxicities Claim Preclinical Hopeful

In an effort to extend cash flow through 2025, Bolt Biotherapeutics announced it is shifting its priorities to focus on two immune-stimulating antibody conjugates (ISAC) programs.

August 11, 2022
·
3 min read
·
Mark Terry
Drug Development

Research Roundup: 21 Genes Linked to Increased Risk of Alzheimer’s and More

A new study on Alzheimer’s disease ties the brain’s immune response to the condition, while scientists have identified a better antibody treatment for cancer and more research news.

August 11, 2022
·
5 min read
·
Mark Terry
Drug Development

Centessa Left with Two Clinical Assets after Second Development Program Halted

Centessa halted ZF874 following the report of an adverse event that involved elevated liver enzymes in a Phase I study. This is the second development program the company has stopped in as many months.

August 11, 2022
·
3 min read
·
Alex Keown
Policy

Sanofi and GSK Defend Zantac in Wake of Renewed Attention Surrounding Lawsuits (Updated)

The makers of ranitidine-based products, such as Sanofi, GSK and Haleon, are reeling from lawsuits related to carcinogenic contamination that could result in billions of dollars in damages.

August 11, 2022
·
4 min read
·
Alex Keown
Business

Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter of 2022.

August 11, 2022
·
18 min read